Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

UNICANCER: Clinical Trials & FDA Approval Profile

UNICANCER (Global / Institutional) sponsors 73 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 55 active protocols (31 recruiting now), 10 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)9.6%
Median Closed Enrollment vs National (145 pts)80 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for UNICANCER
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)73
Active Pipeline (Recruiting Now)55 (31)
Completed vs Stopped Early10 / 7 (9.6%)
Median Closed Actual Enrollment80 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With UNICANCER
Hospital Research SiteLocationShared Protocols
Centre Antoine-LacassagneNice29
Gustave RoussyVillejuif, Île-de-France Region25
Centre Léon BérardLyon25

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by UNICANCER
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07106632Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic TestsPhase IIIRECRUITING
NCT06680596Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd TherapyPhase IIRECRUITING
NCT07237256Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant RibociclibPhase IIIRECRUITING
NCT06078384Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBCPhase IIRECRUITING
NCT05973864Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and SurgeryPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the UNICANCER Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI